- Home
- TARA vs SRZN Comparison
TARA vs SRZN Comparison
Compare TARA & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TARA | SRZN |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | 59 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.1M | 271.6M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TARA | SRZN |
|---|---|---|
| Price | $3.89 | $18.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $24.40 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 313.1K | 185.3K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.25 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,948,000.00 | ★ $3,477,000.00 |
| Revenue This Year | N/A | $75.35 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.02 | $11.30 |
| 52 Week High | $7.82 | $35.00 |
Technical Indicators
Market Signals| Indicator | TARA | SRZN |
|---|---|---|
| Relative Strength Index (RSI) | 39.12 | 31.85 |
| Support Level | $3.73 | $17.44 |
| Resistance Level | $4.17 | $24.13 |
| Average True Range (ATR) | 0.14 | 1.45 |
| MACD | -0.01 | -0.42 |
| Stochastic Oscillator | 17.91 | 19.29 |
Price Performance
Historical ComparisonAbout TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).